News
Eli Lilly Announces Phase III Data for Retatrutide: 28.3% Weight Loss and Significant Systemic Anti-Inflammatory Effects, Ushering in the Triple-Target Era in GLP-1 Therapy
First Oral Small-Molecule GLP-1 Drug Orforglipron (Foundayo™) Approved – A New Era in Obesity Treatment